ScreenerHero

IXHL Incannex Healthcare Inc.

NAS · US · Healthcare · Drug Manufacturers - Specialty & Generic · incannex.com
3.180USD+0.32%Mkt Cap: 39.89M $P/E: —

Incannex Healthcare Inc., a clinical-stage biopharmaceutical company, engages in the research and development of psychedelic medicines and therapies for patients with chronic diseases in Australia. The company develops I…

Industry Peers

Drug Manufacturers - Specialty & Generic
Screen all
MRK
Merck KGaA
$66.23BUSDP/E 25.7
TAK
Takeda Pharmaceutical Company Limited
$58.68BUSD
TEVA
Teva Pharmaceutical Industries Limited
$45.70BUSDP/E 65.3
GALD
Galderma Group AG
$43.27BUSDP/E 56.1
HLN
Haleon plc
$39.67BUSDP/E 18.4
SDZ
Sandoz Group AG
$34.93BUSDP/E 60.5
HLN
Haleon plc
$32.73BUSDP/E 19.0
ZOE
Zoetis Inc.
$28.56BUSDP/E 12.2
ZTS
Zoetis Inc.
$29.57BUSDP/E 11.8
UTHR
United Therapeutics Corporation
$23.38BUSDP/E 19.5
VTRS
Viatris Inc.
$20.09BUSD
SOBI
Swedish Orphan Biovitrum AB (publ)
$14.43BUSDP/E 112.9
NBIX
Neurocrine Biosciences, Inc.
$14.58BUSDP/E 21.0
IPN
Ipsen S.A.
$12.99BUSDP/E 23.5
ELAN
Elanco Animal Health Incorporated
$11.17BUSD
RDY
Dr. Reddy's Laboratories Limited
$10.22BUSDP/E 27.9
KRK
Krka, d. d.
$8.66BUSDP/E 19.3
ALKS
Alkermes plc
$6.95BUSDP/E 109.1
HIMS
Hims & Hers Health, Inc.
$6.89BUSD
AMRX
Amneal Pharmaceuticals, Inc.
$6.84BUSDP/E 40.1

Key Statistics

Company
Market Cap39.89M USD
Enterprise Value-27.85M USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-19.30M USD
Revenue/Share—
Last Price3.180 USD
Fiscal Year EndJun 2026
MR QuarterJun 2026
Employees12
CountryUS
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-1.86
PEG—
EV/EBITDA1.54
EV/Revenue—
P/S—
P/B0.59
EPS (TTM)-1.64
EPS (Forward)-1.70
52W Range
2.4905% of range15.48
52W High15.48 USD
52W Low2.490 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-47.80%
ROA-24.58%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-15.85M USD
CapEx (TTM)277.00K USD
FCF Margin—
FCF Yield-23.20%
Net Debt-67.61M USD
Net Debt/EBITDA3.73
Balance Sheet
Debt/Equity0.14
Current Ratio48.81
Quick Ratio48.61
Book Value/Sh5.37 USD
Cash/Share5.40 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:30
Split DateFeb 27, 2026
Analyst Consensus
Rating1.0 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)18.70 USD
Upside (mean)+488.1%
Target Range18.05 USD – 19.36 USD
18.05+488.1% to mean19.36
# Analysts2
Ownership
Shares Out.12.54M
Float10.18M
Insiders11.77%
Institutions3.64%
Short Interest
Short Ratio8.9d
Short % Float5.78%
Short % Out.5.71%
Shares Short716.31K
Short (prev mo.)812.49K
Technical
SMA 503.306 (-3.8%)
SMA 2005.062 (-37.2%)
Beta2.82
S&P 52W Chg16.45%
Avg Vol (30d)78.18K
Avg Vol (10d)67.26K
Technical Indicators
RSI (14)44.0
MACD-0.0376
MACD Signal-0.0136
MACD Hist.-0.0240
BB Upper3.565 USD
BB Middle3.313 USD
BB Lower3.061 USD
BB Width15.21%
ATR (14)0.1703 USD
Vol Ratio (20d)0.33x